Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Genentech |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00113217 |
Primary Objectives:
Secondary Objectives (Clinical):
Secondary Objectives (Preclinical):
Condition | Intervention | Phase |
---|---|---|
Renal Cell Carcinoma Kidney Cancer |
Drug: Bevacizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma |
Estimated Enrollment: | 50 |
Study Start Date: | February 2005 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Bevacizumab
|
Drug: Bevacizumab
10 mg/kg IV on day 1 of each 14-day cycle.
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
U.T.M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Eric Jonasch, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T.M.D. Anderson Cancer Center ( Eric Jonasch, MD/Assistant Professor ) |
Study ID Numbers: | 2003-0982 |
Study First Received: | June 6, 2005 |
Last Updated: | October 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00113217 |
Health Authority: | United States: Institutional Review Board |
Renal Cell Carcinoma Kidney Cancer Bevacizumab Avastin RCC |
Urogenital Neoplasms Renal cancer Bevacizumab Urologic Neoplasms Kidney cancer Carcinoma Antibodies Urologic Diseases |
Kidney Neoplasms Carcinoma, Renal Cell Kidney Diseases Adenocarcinoma Urinary tract neoplasm Immunoglobulins Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Antineoplastic Agents Therapeutic Uses Growth Substances |
Physiological Effects of Drugs Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |